{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:28:20Z","timestamp":1781332100077,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Pharma Mar, S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,8,15]]},"DOI":"10.1007\/s10637-018-0674-x","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T23:40:40Z","timestamp":1541720440000},"page":"674-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors"],"prefix":"10.1007","volume":"37","author":[{"given":"Elena","family":"Elez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gomez-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Soto Matos-Pita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillem","family":"Argiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya","family":"Coronado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Betrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Fudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Zaragoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7305-5561","authenticated-orcid":false,"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"674_CR1","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1158\/1078-0432.CCR-08-2710","volume":"15","author":"EL Schwartz","year":"2009","unstructured":"Schwartz EL (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15:2594\u20132601. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2710","journal-title":"Clin Cancer Res"},{"key":"674_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/bcp.13126","volume":"83","author":"D Bates","year":"2017","unstructured":"Bates D, Eastman A (2017) Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol 83:255\u2013268. https:\/\/doi.org\/10.1111\/bcp.13126","journal-title":"Br J Clin Pharmacol"},{"key":"674_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/1535-7163.MCT-13-0791","volume":"13","author":"E Mukhtar","year":"2014","unstructured":"Mukhtar E, Adhami VM, Mukhtar H (2014) Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther 13:275\u2013284. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0791","journal-title":"Mol Cancer Ther"},{"key":"674_CR4","doi-asserted-by":"publisher","first-page":"10164","DOI":"10.1021\/ja404578u","volume":"135","author":"MJ Martin","year":"2013","unstructured":"Martin MJ, Coello L, Fernandez R, Reyes F, Rodriguez A, Murcia C, Garranzo M, Mateo C, Sanchez-Sancho F, Bueno S, de Eguilior C, Francesch A, Munt S, Cuevas C (2013) Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds. J Am Chem Soc 135:10164\u201310171. https:\/\/doi.org\/10.1021\/ja404578u","journal-title":"J Am Chem Soc"},{"key":"674_CR5","doi-asserted-by":"publisher","first-page":"13817","DOI":"10.1073\/pnas.1408124111","volume":"111","author":"AE Prota","year":"2014","unstructured":"Prota AE, Bargsten K, Diaz JF, Marsh M, Cuevas C, Liniger M, Neuhaus C, Andreu JM, Altmann KH, Steinmetz MO (2014) A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc Natl Acad Sci U S A 111:13817\u201313821. https:\/\/doi.org\/10.1073\/pnas.1408124111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"674_CR6","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1021\/cb400461j","volume":"8","author":"B Pera","year":"2013","unstructured":"Pera B, Barasoain I, Pantazopoulou A, Canales A, Matesanz R, Rodriguez-Salarichs J, Garcia-Fernandez LF, Moneo V, Jimenez-Barbero J, Galmarini CM, Cuevas C, Penalva MA, Diaz JF, Andreu JM (2013) New interfacial microtubule inhibitors of marine origin, PM050489\/PM060184, with potent antitumor activity and a distinct mechanism. ACS Chem Biol 8:2084\u20132094. https:\/\/doi.org\/10.1021\/cb400461j","journal-title":"ACS Chem Biol"},{"key":"674_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.bcp.2014.01.026","volume":"88","author":"M Martinez-Diez","year":"2014","unstructured":"Martinez-Diez M, Guillen-Navarro MJ, Pera B, Bouchet BP, Martinez-Leal JF, Barasoain I, Cuevas C, Andreu JM, Garcia-Fernandez LF, Diaz JF, Aviles P, Galmarini CM (2014) PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. Biochem Pharmacol 88:291\u2013302. https:\/\/doi.org\/10.1016\/j.bcp.2014.01.026","journal-title":"Biochem Pharmacol"},{"key":"674_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4086-2","volume":"18","author":"CM Galmarini","year":"2018","unstructured":"Galmarini CM, Martin M, Bouchet BP, Guillen-Navarro MJ, Martinez-Diez M, Martinez-Leal JF, Akhmanova A, Aviles P (2018) Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells. BMC Cancer 18:164. https:\/\/doi.org\/10.1186\/s12885-018-4086-2","journal-title":"BMC Cancer"},{"key":"674_CR9","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","volume":"24","author":"MG Kris","year":"2006","unstructured":"American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932\u20132947. https:\/\/doi.org\/10.1200\/JCO.2006.06.9591","journal-title":"J Clin Oncol"},{"key":"674_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","volume":"33","author":"FH Hausheer","year":"2006","unstructured":"Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15\u201349. https:\/\/doi.org\/10.1053\/j.seminoncol.2005.12.010","journal-title":"Semin Oncol"},{"key":"674_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fphar.2017.00086","volume":"8","author":"N Kerckhove","year":"2017","unstructured":"Kerckhove N, Collin A, Conde S, Chaleteix C, Pezet D, Balayssac D (2017) Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol 8:86. https:\/\/doi.org\/10.3389\/fphar.2017.00086","journal-title":"Front Pharmacol"},{"key":"674_CR12","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00520-014-2242-z","volume":"22","author":"AJ Beijers","year":"2014","unstructured":"Beijers AJ, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22:1999\u20132007. https:\/\/doi.org\/10.1007\/s00520-014-2242-z","journal-title":"Support Care Cancer"},{"key":"674_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, investigators E (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914\u2013923. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6","journal-title":"Lancet"},{"key":"674_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/1097-0142(19890815)64:4<801::AID-CNCR2820640406>3.0.CO;2-E","volume":"64","author":"HE Hirvonen","year":"1989","unstructured":"Hirvonen HE, Salmi TT, Heinonen E, Antila KJ, Valimaki IA (1989) Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy. Cancer 64:801\u2013805","journal-title":"Cancer"},{"key":"674_CR15","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"AD Seidman","year":"2008","unstructured":"Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642\u20131649. https:\/\/doi.org\/10.1200\/JCO.2007.11.6699","journal-title":"J Clin Oncol"},{"key":"674_CR16","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","volume":"18","author":"HJ Burstein","year":"2000","unstructured":"Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212\u20131219. https:\/\/doi.org\/10.1200\/JCO.2000.18.6.1212","journal-title":"J Clin Oncol"},{"key":"674_CR17","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin\/5-Fluorouracil\/Leucovorin in the Adjuvant Treatment of Colon Cancer I (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351. https:\/\/doi.org\/10.1056\/NEJMoa032709","journal-title":"N Engl J Med"},{"key":"674_CR18","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/annonc\/mdi193","volume":"16","author":"HP Kalofonos","year":"2005","unstructured":"Kalofonos HP, Aravantinos G, Kosmidis P, Papakostas P, Economopoulos T, Dimopoulos M, Skarlos D, Bamias A, Pectasides D, Chalkidou S, Karina M, Koutras A, Samantas E, Bacoyiannis C, Samelis GF, Basdanis G, Kalfarentzos F, Fountzilas G (2005) Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 16:869\u2013877. https:\/\/doi.org\/10.1093\/annonc\/mdi193","journal-title":"Ann Oncol"},{"key":"674_CR19","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","volume":"22","author":"J Cassidy","year":"2004","unstructured":"Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084\u20132091. https:\/\/doi.org\/10.1200\/JCO.2004.11.069","journal-title":"J Clin Oncol"},{"key":"674_CR20","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S0959-8049(99)00149-5","volume":"35","author":"F Maindrault-Goebel","year":"1999","unstructured":"Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M, de Gramont A (1999) Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35:1338\u20131342","journal-title":"Eur J Cancer"},{"key":"674_CR21","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/annonc\/mds208","volume":"23","author":"AA Argyriou","year":"2012","unstructured":"Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, Cacciavillani M, Lonardi S, Santos C, Cortinovis D, Cazzaniga M, Kalofonos HP (2012) Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 23:3116\u20133122. https:\/\/doi.org\/10.1093\/annonc\/mds208","journal-title":"Ann Oncol"},{"key":"674_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/02841860701355055","volume":"46","author":"AA Argyriou","year":"2007","unstructured":"Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP, Chroni E (2007) Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 46:1131\u20131137. https:\/\/doi.org\/10.1080\/02841860701355055","journal-title":"Acta Oncol"},{"key":"674_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000271272","volume":"31","author":"AM Peters","year":"2010","unstructured":"Peters AM, Glass DM (2010) Use of body surface area for assessing extracellular fluid volume and glomerular filtration rate in obesity. Am J Nephrol 31:209\u2013213. https:\/\/doi.org\/10.1159\/000271272","journal-title":"Am J Nephrol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0674-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:33:45Z","timestamp":1678559625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0674-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8,15]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0674-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"25 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A Soto Matos-Pita, C Coronado, J Iglesias, S Fudio, and K Zaragoza are employees of Pharma Mar, S.A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}